A catalase inhibitor: Targeting the NADPH-binding site for castration-resistant prostate cancer therapy.

ABSTRACT: Catalase (CAT) is an important antioxidant enzyme that breaks down H₂O₂ into water and oxygen. Inhibitor-modulating CAT activity in cancer cells is emerging as a potential anticancer strategy. However, the discovery of CAT inhibitors towards the heme active center located at the bottom of long and narrow channel has made little progress. Therefore, targeting new binding site is of great importance for the development of efficient CAT inhibitors. Here, the first NADPH-binding site inhibitor of CAT, BT-Br, was designed and synthesized successfully. The cocrystal structure of BT-Br-bound CAT complex was determined with a resolution of 2.2 Å (PDB ID:8HID), which showed clearly that BT-Br bound at the NADPH-binding site. Furthermore, BT-Br was demonstrated to induce ferrop

SUBMITTER: Cao YY 

PROVIDER: S-EPMC10213376 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature